Titles and Affiliations

Professor of Oncology
Member, Breast Cancer Program
Sidney Kimmel Comprehensive Cancer Center
Translational Breast Cancer Research Consortium
Johns Hopkins University School of Medicine
Baltimore, Maryland

Research area

Accelerating new treatments to benefit patients through focused clinical trials.

Impact

As our understanding of the complexity of breast cancer continues to evolve, clinical research requires the design of smaller, focused trials that are enriched with studies to reveal the underlying biology. The Translational Breast Cancer Research Consortium (TBCRC) was created to address this unmet need. TBCRC trials often include novel combinations of drugs, or they address highly specific questions that would go unanswered in larger, pharma-initiated studies. These studies are typically intensive in biospecimen acquisition, require specialized imaging, enroll fewer patients across a larger number of centers, and require coordinated planning among lab researchers, clinical trialists, biostatisticians, research coordinators, and patient advocates. Under the leadership of Dr. Antonio Wolff, TBCRC coalesces 19 leading clinical centers across the United States to organize these trials, fostering collaboration among the greatest minds in breast cancer. 

Progress Thus Far

To date, TBCRC has approved 59 clinical trials. From these studies, over 5,600 patients participated in important clinical research. BCRF is a primary funder of TBCRC, and its contributions total nearly $19 million. This support helped yield 150-plus scientific peer-reviewed presentations and publications from TBCRC. These findings have been shared with the global breast cancer community and contributed to a more nuanced understanding of breast cancer progression and treatment. 

What’s next

Over the next year, TBCRC will continue to enroll patients on 17 active TBCRC trials, and 2 were recently approved. The two newest additions will study a combination immunotherapy in breast cancers that are PDL1 negative (a marker typically required for immunotherapies) or did not respond to prior immunotherapy, and the impact of the COVID-19 pandemic on the willingness of patients to participants in clinical trials. 
 

Biography

Dr. Antonio Wolff is a Professor of Oncology at Johns Hopkins University (JHU) and a member of the Johns Hopkins Kimmel Cancer Center (Baltimore, MD, USA). He received his medical degree at the Universidade Federal do Rio de Janeiro in Brazil and trained in medical oncology at Johns Hopkins. He is an Associate Editor of the Journal of Clinical Oncology, Chair of the ECOG-ACRIN Breast Cancer Committee, and Chief Operating Officer for the Translational Breast Cancer Research Consortium (TBCRC). He is a Fellow of the American Society of Clinical Oncology (FASCO) and past Chair of its Clinical Practice Guidelines Committee. His research interests include new treatment strategies, the development and implementation of prognostic and predictive biomarkers (tissue, blood, and imaging) in clinical practice, and on how to improve the survivorship experience of breast cancer patients and their caregivers. He is a Susan G. Komen Scholar, recipient of a Cancer Clinical Investigator Team Leadership Award from the US National Cancer Institute, and has been recognized since 2017 by Clarivate Analytics (Thomson Reuters) as one of the world’s most highly cited researchers (top 1% in clinical medicine). He maintains an active clinical practice dedicated to the care of patients with breast cancer and was inducted in 2018 as a member of the JHU Miller Coulson Academy of Clinical Excellence. In 2018, Dr. Wolff was recognized as one of 125 Living the Hopkins Mission Honorees, who were selected for their outstanding dedication to the institution’s core values of excellence and discovery, leadership and integrity, diversity and inclusion, and respect and collegiality, as part of the 125th anniversary celebration of the JHU School of Medicine.

BCRF Investigator Since

2007

Areas of Focus